The Gln27Glu β2-adrenoceptor polymorphism slows the onset of desensitization of cardiac functional responses in vivo

Pharmacogenetics

Volumn 13, Issue 2, 2003, Pages 59-66

  Bruck, Heike ^c   Leineweber, Kirsten ^c   Büscher, Rainer ^c   Ulrich, Anke ^c   Radke, Joachim ^c   Insel, Paul A ^a   Brodde, Otto Erich ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^c NONE

Author keywords

2 adrenoceptor polymorphism; 2 adrenoceptors; Chronotropism; Inotropism; Terbutaline

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; TERBUTALINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; GLYCINE; PRIMER DNA;

ADULT; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DESENSITIZATION; DRUG EFFECT; DRUG INFUSION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEART HEMODYNAMICS; HEART MUSCLE CONTRACTILITY; HEART RATE VARIABILITY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; PROTEIN VARIANT; SYSTOLE; WILD TYPE; CHEMISTRY; COMPARATIVE STUDY; DRUG POTENTIATION; DRUG RESISTANCE; GENE FREQUENCY; GENETICS; HEART; HEART CONTRACTION; HEART RATE; HOMOZYGOTE; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

ADRENERGIC BETA-AGONISTS; ADULT; DNA PRIMERS; DRUG RESISTANCE; FEMALE; GENE FREQUENCY; GENOTYPE; GLUTAMIC ACID; GLYCINE; HEART; HEART RATE; HOMOZYGOTE; HUMANS; MALE; MYOCARDIAL CONTRACTION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-2; TERBUTALINE;

EID: 0037330909     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200302000-00001     Document Type: Article

References (28)

1. Kaumann AJ, Molenaar P. Modulation of human cardiac function through 4β-adrenoceptor populations. Naunyn-Schmiedeberg's Arch Pharmacol 1997; 355:667-681.
2. Brodde O-E, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999; 51:651-690.
3. Port JD, Bristow MR. Altered β-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol 2001; 33:887-905.
4. 1-Adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? J Mol Med 2000; 78:87-93.
5. 1-adrenergic receptor. J Biol Chem 1999; 274:12670-12674.
6. Büscher R, Herrmann V, Insel PA. Human adrenoceptor polymorphisms: evolving recognition of clinical importance. Trends Pharmacol Sci 1999; 20:94-99.
7. Liggett SB. Pharmacogenetics of beta-1- and beta-2-adrenergic receptors. Pharmacology 2000; 61:167-173.
8. 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33:9414-9419.
9. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993; 268:23116-23121.
10. 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acac Sci USA 1996; 93:10483-10488.
11. McDevitt DG. In vivo studies on the function of cardiac β-adrenoceptors in man. Eur Heart J 1989; 10:22-28
12. 1- and β2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 1991; 43:203-242.
13. Büscher R, Belger H, Eilmes KJ, Tellkamp R, Radke J, Dhein S, et al. In-vivo studies do not support a major functional role for the Gly389Arg β1-adrenoceptor polymorphism in humans. Pharmacogenetics 2001; 11:199-205
14. 1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics 2001; 11:191-197.
15. 2-adrenoceptors. Circulation 2001; 103:1048-1050.
16. 2-adrenoceptor in vivo function in humans: attenuation by ketotifen. J Cardiovasc Pharmacol 1992; 20:434-439.
17. 2-adrenoceptor-mediated positive inotropic effects: attenuation by ketotifen. Cardiovasc Res 1998; 40:211-222.
18. Daul A, Hermes U, Schäfers RF, Wenzel R, von Birgelen C, Brodde O-E. The β-adrenoceptor subtype(s) mediating adrenaline- and dobutamine-induced blood pressure and heart rate changes in healthy volunteers. Int J Clin Pharmacol Ther 1995; 33:140-148.
19. 1-adrenoceptor antagonist treatment. J Am Coll Cardiol 1994; 23:1224-1233.
20. 2-Adrenergic receptor polymorphisms at codon 16, cardiovascular phenotypes and essential hypertension in whites and African Americans. Am J Hypertens 2000; 13:1021-1026.
21. Belz GG. Systolic time intervals: a method to assess cardiovascular drug effects in humans. Eur J Clin Invest 1995; 25:35-41.
22. Gratze G, Fortin J, Labugger R, Binder A, Kotanko P, Timmermann B, et al. β-2 Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension 1999; 33:1425-1430.
23. 2-Adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. Am Heart J 2000; 139:537-542.
24. 2-Adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension 2000; 36:371-375
25. 2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 2001; 345:1030-1035.
26. Dewar JC, Wheatley AP, Venn A, Morrison JF, Britton J. Hall IP. Beta2-adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population Clin Exp Allergy 1998; 28:442-448.
27. 2-adrenergic receptor regulate receptor expression. J Clin Invest 1998; 102:1927-1932.
28. Scott MG, Swan C, Wheatley AP, Hall IP. Identification of novel polymorphisms within the promoter region of the human β2 adrenergic receptor gene. Br J Pharmacol 1999; 126:841-844.